Your browser doesn't support javascript.
loading
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.
Wang, Na; Hu, Xuelian; Cao, Wenyue; Li, Chunrui; Xiao, Yi; Cao, Yang; Gu, Chaojiang; Zhang, Shangkun; Chen, Liting; Cheng, Jiali; Wang, Gaoxiang; Zhou, Xiaoxi; Zheng, Miao; Mao, Xia; Jiang, Lijun; Wang, Di; Wang, Qiuxiang; Lou, Yaoyao; Cai, Haodong; Yan, Dandan; Zhang, Yicheng; Zhang, Tongcun; Zhou, Jianfeng; Huang, Liang.
Affiliation
  • Wang N; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hu X; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
  • Cao W; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Li C; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
  • Xiao Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cao Y; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
  • Gu C; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhang S; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
  • Chen L; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cheng J; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
  • Wang G; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhou X; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
  • Zheng M; College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, China.
  • Mao X; Wuhan Bio-Raid Biotechnology Co., Ltd., Wuhan, China; and.
  • Jiang L; Wuhan Bio-Raid Biotechnology Co., Ltd., Wuhan, China; and.
  • Wang D; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang Q; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
  • Lou Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Cai H; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
  • Yan D; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhang Y; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
  • Zhang T; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhou J; Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
  • Huang L; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Blood ; 135(1): 17-27, 2020 01 02.
Article in En | MEDLINE | ID: mdl-31697824
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Antigen, T-Cell / Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Drug Resistance, Neoplasm / Antigens, CD19 / Sialic Acid Binding Ig-like Lectin 2 / Cell- and Tissue-Based Therapy / Neoplasm Recurrence, Local Type of study: Observational_studies / Prognostic_studies Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 2020 Document type: Article Affiliation country: China Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Antigen, T-Cell / Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Drug Resistance, Neoplasm / Antigens, CD19 / Sialic Acid Binding Ig-like Lectin 2 / Cell- and Tissue-Based Therapy / Neoplasm Recurrence, Local Type of study: Observational_studies / Prognostic_studies Limits: Adolescent / Adult / Aged / Child / Female / Humans / Male / Middle aged Language: En Journal: Blood Year: 2020 Document type: Article Affiliation country: China Country of publication: United States